Abivax (NASDAQ:ABVX) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Abivax (NASDAQ:ABVX) in a research report report published on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $160.00 price target on the stock.

Several other brokerages have also recently issued reports on ABVX. BTIG Research reaffirmed a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Wednesday, February 25th. Morgan Stanley increased their price target on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Finally, Wedbush started coverage on shares of Abivax in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $136.69.

Abivax Price Performance

Shares of NASDAQ ABVX opened at $122.75 on Monday. The stock has a market cap of $9.71 billion, a price-to-earnings ratio of -29.37 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. Abivax has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The firm’s 50-day simple moving average is $118.98 and its 200 day simple moving average is $109.39.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The business had revenue of ($4.92) million during the quarter. As a group, research analysts anticipate that Abivax will post -2.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

Several institutional investors have recently modified their holdings of ABVX. EverSource Wealth Advisors LLC lifted its holdings in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the period. First Horizon Corp bought a new position in Abivax in the 3rd quarter valued at $36,000. Bank of America Corp DE increased its position in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. Hantz Financial Services Inc. purchased a new stake in shares of Abivax during the 3rd quarter valued at $52,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares during the period. 47.91% of the stock is owned by institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.